CMS Grants Permanent Product-specific Q-Code for Fresenius Kabi’s Stelara Biosimilar
The Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Fresenius Kabi’s Otulfi (ustekinumab-aauz), an ustekinumab biosimilar referencing Stelara.